|
A test to predict toxicity to 5-FU/capecitabine-based chemotherapy
TheraGuide 5-FU™ is the most comprehensive test available for assessing the risk of toxicity due to 5-FU/capecitabine-based chemotherapy. It detects variations in 2 genes, dihydropyrimidine dehydrogenase (DPYD) and thymidylate synthetase (TYMS), that are responsible for a significant portion of serious adverse reactions to 5-FU-based therapy. TheraGuide 5-FU™ is a simple blood test that provides comprehensive analysis of DPYD and TYMS gene variations to predict and help prevent 5-FU-related adverse events.
Please visit the myriadtests.com website to learn more about how to identify patients at risk for developing 5-FU related toxicity.
Related Links
|
